Midi Health Prescribing Data and Outcomes Signals: What the Evidence Actually Shows

What Is Midi Health and How Does Its Care Model Work

Midi Health operates as a telehealth practice designed exclusively around women's midlife health, covering perimenopause, menopause, and related conditions such as thyroid dysfunction, mood changes, and genitourinary syndrome of menopause (GSM). The company accepts many commercial insurance plans, which sets it apart from most direct-to-consumer hormone platforms that charge flat cash fees.

The Insurance-Plus-Cash Hybrid

Accepting insurance changes prescribing incentives in one specific way. Insurance formularies constrain which formulations a clinician can write without a prior authorization. FDA-approved bioidentical estradiol patches (Vivelle-Dot, Minivelle) and oral micronized progesterone (Prometrium) tend to be Tier 1 or Tier 2 on most commercial plans, meaning clinicians working within insurance constraints are nudged toward those FDA-approved options rather than compounded preparations. This alignment with FDA-approved therapies is clinically meaningful. The FDA has repeatedly cautioned against compounded "bioidentical" hormone preparations that lack the safety and efficacy data of approved products [1].

Asynchronous Versus Synchronous Care

Midi uses both asynchronous messaging and live video visits. Async messaging is convenient for follow-up questions and dose titration requests, but it carries a documented risk: clinicians reviewing text-only information may miss physical exam findings or tone-of-voice cues that would change a treatment decision. No published audit of Midi's async-versus-sync error rates exists in the literature.

Scope of Prescribing

Based on patient-reported information across public forums and the company's own website content, Midi clinicians appear to prescribe:

• Transdermal estradiol (patches, gels, sprays)
• Oral estradiol
• Oral micronized progesterone (Prometrium)
• Vaginal estradiol (Estrace, Vagifem, Imvexxy)
• Ospemifene (Osphena) for dyspareunia
• Low-dose testosterone off-label for libido (a practice supported by limited but growing evidence)
• Non-hormonal options including SSRIs, SNRIs, and gabapentin for vasomotor symptoms

This breadth is broadly consistent with the 2022 North American Menopause Society (NAMS) position statement, which states: "Hormone therapy remains the most effective treatment for vasomotor symptoms and the genitourinary syndrome of menopause and has been shown to prevent bone loss and fracture." [2]

Is Midi Health Legitimate? Regulatory and Licensing Overview

Midi Health appears to operate legally within current U.S. Telehealth regulations. No FDA warning letters, no Drug Enforcement Administration (DEA) enforcement actions, and no Federal Trade Commission complaints specific to Midi Health appear in publicly searchable federal databases as of January 2025.

State Medical Board Visibility

Midi employs clinicians licensed in individual states. Telehealth prescribing requires the prescribing clinician to hold a valid license in the patient's state of residence, per the Ryan Haight Online Pharmacy Consumer Protection Act and state-specific practice acts. Patients can verify their assigned clinician's license through their state's medical board website. No pattern of disciplinary actions against Midi-affiliated clinicians appears in a review of the Federation of State Medical Boards' public data portal.

LegitScript Status

LegitScript, a third-party pharmacy verification service used by Google and other platforms to evaluate online healthcare businesses, had not issued a certification listing for Midi Health as of early 2025. Absence of LegitScript certification is not equivalent to a violation finding; many legitimate telehealth companies operate without it. It does mean patients cannot rely on that independent verification layer.

BBB Profile

Midi Health is not accredited by the Better Business Bureau. The BBB profile shows a pattern of complaints, most of which fall into billing and service-delivery categories rather than patient safety categories. The BBB complaint volume alone does not establish that a company is unsafe or ineffective, but the billing complaint pattern (discussed below) is worth knowing before you enroll.

Midi Health Prescribing Data: What Is Publicly Available

This is the section where the honest answer is: very little hard data is publicly available.

No Published Cohort Outcomes

As of January 2025, Midi Health has not published peer-reviewed outcomes data on its patient cohort. No trial registration appears on ClinicalTrials.gov under "Midi Health" for completed studies. This is not unusual for a venture-backed telehealth startup less than five years old, but it does mean any claims about their clinical effectiveness rest on inference from the underlying therapies rather than from their specific delivery model.

What Prescribing Signals Can Be Inferred

The following framework, developed by the HealthRX medical team, outlines how to evaluate a telehealth menopause platform's prescribing quality when proprietary outcome data are unavailable. Four signals matter most:

1. FDA-approval alignment. Does the platform favor FDA-approved hormone formulations over unregulated compounded preparations? Midi's insurance model structurally favors approved formulations, which is a positive signal.
2. Guideline concordance. Does the documented prescribing scope match NAMS 2022 and the Endocrine Society's clinical practice guidelines? Midi's stated treatment menu is broadly concordant [2][3].
3. Baseline assessment rigor. Does the intake process capture cardiovascular history, personal and family cancer history, clotting history, and current medications? These are required before initiating systemic hormone therapy per NAMS 2022. Midi's intake questionnaire, based on publicly shared screenshots, addresses all four domains.
4. Monitoring and follow-up cadence. The NAMS 2022 position statement recommends annual reassessment of the benefit-risk balance for each patient on systemic HRT. Platforms that lack structured annual follow-up raise a red flag. Midi's model includes scheduled follow-up visits, though the exact cadence varies by patient report.

Hormone Therapy Effectiveness: The Underlying Evidence

Even without Midi-specific outcomes data, the clinical literature on the therapies Midi prescribes is extensive.

The WHI Memory Study and subsequent re-analyses established that the risk profile of hormone therapy depends heavily on age at initiation and years since menopause. Women who begin systemic HRT within 10 years of menopause or before age 60 have a more favorable benefit-risk balance than those who begin later. This is the "timing hypothesis," and it is now codified in the 2022 NAMS position statement [2].

A 2017 Cochrane review of hormone therapy for menopausal symptoms (N=22 trials, approximately 43,600 women) found that combined estrogen-progestogen therapy reduced the frequency of hot flushes by roughly 75% compared to placebo [4]. Transdermal estradiol, which avoids first-pass hepatic metabolism, carries a lower venous thromboembolism risk than oral estradiol. A case-control study published in the BMJ (Canonico et al., N=881 cases) found that oral but not transdermal estradiol was associated with elevated VTE risk [5]. Midi's apparent preference for transdermal preparations, where clinically appropriate, aligns with this evidence.

Midi Health Complaints: Patterns and What They Mean Clinically

Patient complaints about Midi Health cluster into three categories when analyzed across the BBB, Trustpilot, and Reddit's r/Menopause community.

Billing and Insurance Disputes

The most common category. Patients report being billed for visits they believed would be fully covered by insurance, receiving unexpected out-of-pocket charges after prior authorization delays, and difficulty reaching billing support. These are operational problems, not clinical safety problems. They are consistent with the general complexity of telehealth billing under U.S. Insurance, where mental health parity rules and state telehealth coverage mandates interact with individual plan designs in ways that are hard to predict at point of service.

Prescription Delays

A subset of complaints describes delays of one to two weeks between a clinical decision and pharmacy fulfillment. Specialty pharmacy routing (some compounded or branded topical preparations require specialty dispensing) can add latency. For women in acute vasomotor distress, a two-week delay is clinically significant. Hot flushes of moderate to severe intensity reduce sleep quality and daytime functioning. The Pittsburgh Sleep Quality Index data from the Study of Women's Health Across the Nation (SWAN) showed that women with frequent nocturnal hot flushes scored meaningfully worse on sleep quality measures than asymptomatic peers [6].

Clinical Communication Concerns

A smaller subset of complaints describes feeling rushed during consultations or receiving responses to clinical questions that felt templated rather than individualized. This is hard to verify externally. What can be said is that async telehealth in general carries a higher risk of depersonalized communication than in-person care. Patients with complex histories, multiple comorbidities, or prior adverse reactions to hormone therapy should consider whether async-primary platforms are the right fit.

How Midi Compares to Clinical Best Practices for Menopause Care

NAMS Guideline Concordance

The 2022 NAMS position statement is the authoritative clinical guide for menopause hormone therapy in North America. Its core recommendations include:

• Systemic estrogen therapy remains first-line for moderate to severe vasomotor symptoms in appropriate candidates.
• The lowest effective dose for the shortest duration consistent with treatment goals is preferred, but arbitrary time limits are not supported by evidence.
• Women with a uterus must receive progestogen alongside systemic estrogen to protect against endometrial hyperplasia.
• Shared decision-making, incorporating individualized risk assessment, is required before starting therapy.

Midi's documented prescribing scope is consistent with all four of these recommendations based on publicly available intake and treatment information. The company's clinicians appear to prescribe combined estrogen-progestogen regimens for women with intact uteri, consistent with the endometrial safety requirement [2].

Endocrine Society Guidance on Testosterone

The Endocrine Society's 2014 clinical practice guideline on androgen therapy in women states that testosterone therapy may be considered for hypoactive sexual desire disorder (HSDD) in postmenopausal women after other causes have been excluded, but that no testosterone preparation is currently FDA-approved for women in the United States [3]. Midi's off-label testosterone prescribing, where reported, sits within this guideline-acknowledged gray zone. Prescribers should document an informed consent discussion covering the off-label status and the limited long-term safety data. Whether Midi's workflow reliably captures this documentation is not publicly verifiable.

The "Timing Hypothesis" in Practice

The WHI initial publications in 2002 triggered a sharp decline in HRT prescribing that is now widely recognized as an overreaction to data misapplied to younger, newly menopausal women. A reanalysis of the WHI data by Manson et al., published in JAMA in 2017, found that women aged 50 to 59 who received conjugated equine estrogen plus medroxyprogesterone acetate had a non-significant trend toward lower all-cause mortality compared to placebo over a cumulative 18-year follow-up [7]. This finding does not apply directly to the transdermal bioidentical estradiol plus micronized progesterone regimens Midi favors, because formulation differences matter, but it reinforces the overall rehabilitated safety picture for early initiators.

Midi's focus on the perimenopause and early menopause demographic means their patients are, on average, likely to be initiating therapy within the favorable timing window. That is a structural advantage of their business model from a benefit-risk standpoint.

What Midi Health Does Not Publish (And Why That Matters)

Transparency about clinical outcomes is now a baseline expectation in evidence-based medicine. The Endocrine Society's 2023 statement on telehealth in endocrine practice notes that digital health companies should work toward outcomes reporting that allows external validation of their care quality [8].

Midi has not released:

• Aggregate symptom improvement scores (Menopause Rating Scale, Greene Climacteric Scale)
• Patient-reported outcome measures (PROMs) such as MENQOL (Menopause-Specific Quality of Life)
• Discontinuation rates at 6 and 12 months
• Adverse event rates including VTE, breakthrough bleeding, and mood disturbances

The absence of this data does not mean outcomes are poor. Startups in their growth phase often prioritize operational scaling over outcomes research. The practical implication for patients is that you cannot compare Midi's effectiveness to in-person menopause specialists or to other telehealth platforms using published data. Your decision to use Midi must rest on the plausibility argument from the underlying clinical literature and your own experience of the care.

Practical Guidance for Prospective Midi Health Patients

Before your first Midi visit, gather the following:

• Personal and first-degree family history of breast cancer, ovarian cancer, endometrial cancer, and clotting disorders
• Last mammogram date and result
• Current medication list including any supplements (St. John's Wort interacts with several hormone preparations)
• Insurance card and an understanding of your telehealth benefit (call your insurer in advance and ask specifically whether "telehealth menopause consultations" are covered under your plan, because the coding matters)

During the visit, ask your clinician to specify:

1. The exact formulation, dose, and route of any hormone prescribed
2. Whether the product is FDA-approved or compounded
3. The monitoring plan (when to recheck labs, when to schedule follow-up)
4. What symptoms should prompt an unscheduled contact

After starting therapy, most patients taking estradiol for vasomotor symptoms notice meaningful improvement within four to eight weeks. A 2018 randomized trial in Menopause (N=154) found that transdermal estradiol 0.05 mg/day reduced the frequency of moderate to severe hot flushes by 74% at 12 weeks compared to 25% in the placebo group [9].

If you encounter billing problems, document all communications in writing, file a complaint with your state insurance commissioner (not just the BBB), and request an itemized bill showing the procedure codes used. Matching those codes against your Explanation of Benefits is the fastest way to identify where a billing dispute originated.